HMCN2

Across TCGA pan-cancer cohorts, HMCN2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HMCN2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher HMCN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HMCN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

UCEC, PDAC, and HNSC are the cancer types where HMCN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.286	1.000	.002	18	view →
PDAC	DFS	Tertile	III,IV	0.567	0.157	.019	11	view →
HNSC	DFS	Quartile	II,III,IV	0.843	1.000	.024	6	view →
LUAD	DFS	Quartile	All	0.945	0.522	.005	4	view →
LSCC	DFS	Median	All	0.615	0.775	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HMCN2–UCEC (OS)

Open the UCEC breakdown →